Equity · Healthcare
BLTE
NASDAQBelite Bio (BLTE)
The line runs 166.87 USD on 10 August through 154.38 USD on 6 November, on a scale from 140 to 200. Days the market did not trade hold the previous close, flat.
- EPS, diluted, year to Dec 2025
- −2.31 USD
- 52-week range
- 98.05 USD – 194 USD
- Avg volume
- 9.7K
as of Nov 6, 2026
Have Belite Bio (BLTE) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Belite Bio insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Apr 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 1 Oct 2026
Buys 0Sells 7Net sold $32.10MOther filings 3
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Scholl Hendrik PeterChief Medical Officer | Sell | 500 | 83K USD |
| 08 Sep 2026 | Lin Yu-HsinChief Executive Officer | Sell | 26,000 | 5.1M USD |
| 08 Sep 2026 | Chuang Hao-YuanChief Financial Officer | Sell | 17,962 | 3.5M USD |
| 04 Sep 2026 | Lin Yu-HsinChief Executive Officer | Sell | 74,435 | 14.0M USD |
| 04 Sep 2026 | Chuang Hao-YuanChief Financial Officer | Sell | 49,433 | 9.3M USD |
| 12 Aug 2026 | Chuang Hao-YuanChief Financial Officer | Sell | 367 | 66K USD |
| 12 Aug 2026 | Lin Yu-HsinChief Executive Officer | Sell | 365 | 66K USD |
| Sold | 7 open-market sales | 169,062 | $32.10M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 29 Oct 2026 | Lin Yu-HsinChief Executive Officer | Other | 5,000 | |
| 29 Oct 2026 | Chuang Hao-YuanChief Financial Officer | Other | 5,000 | |
| 24 Sep 2026 | Chen Wan-ShanDirector | Other | 13,796 | 6K USD |
Which funds hold Belite Bio (BLTE)?
7 of the 45 institutional funds we track reported a Belite Bio position for the quarter ended 30 Jun 2026 — a combined 204.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Held (±25%) | 494,564 | 76.2M USD | −13.2% |
| Maverick Capital | New position | 396,311 | 61.0M USD | |
| Citadel Advisors | Added | 186,168 | 28.7M USD | +9,171.3% |
| Duquesne Family Office | Held (±25%) | 106,100 | 16.3M USD | |
| Renaissance Technologies | Held (±25%) | 55,763 | 8.6M USD | +7.2% |
| Point72 Asset Management | New position | 51,186 | 7.9M USD | |
| Two Sigma Investments | New position | 38,100 | 5.9M USD | |
| Tudor Investment Corp | Exited |
What has been filed or recorded for Belite Bio (BLTE)?
The filings we hold for Belite Bio, newest first: 1 fails-to-deliver day and 4 reported financial figures, the latest dated 07 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,740 shares | 271K USD notional · 0.004% of shares out |
| 31 Dec 2025 | Financials | Net income | −77.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.31 USD | fiscal year |
| 31 Dec 2025 | Financials | Total assets | 780.6M USD | at period end |
| 31 Dec 2025 | Financials | Total equity | 770.5M USD | at period end |
Belite Bio (BLTE): frequently asked questions
What did Belite Bio shares close at?
Belite Bio closed at 154.38 USD on 6 Nov 2026, up 8.11% on the close before. That is the end-of-day price from Finazon, not a live quote.
Have Belite Bio insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Belite Bio insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Apr 2026, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Belite Bio?
7 of the 45 funds we track reported a Belite Bio position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Maverick Capital and Citadel Advisors. See Funds
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 31 Dec 2025